Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073 is registered in ClinicalTrials.gov with ArriVent BioPharma, Inc. as lead sponsor.

NCT NCT05364073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Lead sponsor
ArriVent BioPharma, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 30, 2022
Completion date
December 31, 2026
Enrollment
160 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, egfr exon 20 mutations, egfr uncommon mutations, including g719x and s768i, her2 exon 20 mutations, metastatic non-small cell lung cancer, non-small cell lung cancer (nsclc)